Moreover, Zhu and colleagues showed in a randomized controlled trial of 140 patients with moderate to severe COPD, that 12 weeks of treatment with salmeterol plus fluticasone decreased tissue expression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ in the larger airways. Here, TNF is linked to chronic obstructive pulmonary disease.